Joseph Gersuk to Retire From AngioDynamics; Mark T. Frost Appointed Chief
ALBANY, N.Y., Nov. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a
leading provider of innovative, minimally invasive medical devices for
vascular access, surgery, peripheral vascular disease and oncology, today
announced Executive Vice President and Chief Financial Officer Joseph Gersuk
will retire from the Company on January 31, 2013. He will be succeeded by Mark
T. Frost, who was most recently Chief Financial Officer and Senior Vice
President of Administration of Albany Molecular Research Inc. (Nasdaq:AMRI).
"Joe has tirelessly served as our CFO for the past five years," said Joseph M.
DeVivo, President and CEO. "During his tenure, he has made many significant
contributions to the Company and most recently led the very successful
integration of operations after our acquisition of Navilyst Medical. On behalf
of the Board of Directors, I would like to thank Joe for his dedication, as
well as participation in the transition of his responsibilities."
"With the integration of Navilyst successfully completed, the Vortex
acquisition closed and our second quarter coming to a close, now is an
excellent time for me to transition out of AngioDynamics and pursue some other
interests which have been on hold," added Mr. Gersuk. "I'm excited about the
Company's future and wish the entire team the very best of success."
Mr. Frost, who most recently served as Chief Financial Officer of AMRI, has
more than 25 years of global financial, administrative and operational
experience, with a strong background in the healthcare industry.
"Mark Frost is a seasoned and well-versed public company CFO who has world
class financial and operational skills and experience to lead the financial
and administrative operations of our Company through its next phase of
growth," said Joseph M. DeVivo. "During his career at AMRI, Smith & Nephew and
General Electric, Mark has demonstrated continuous commitment to operational
excellence and the successful execution of strategic business initiatives. In
addition to his previous responsibilities, Mark has led Corporate Development,
IT, Communications, Legal and a variety of other mission critical functions.
The strength of Mark's experience and skills make him an excellent fit and a
solid complement to our strong leadership team."
Prior to AMRI, he served five years as vice president of finance at Smith &
Nephew Endoscopy, a global medical device division of Smith & Nephew PLC with
approximately $570 million in revenue. Mr. Frost was recruited to Smith &
Nephew after a 14 year career with General Electric where he last served as
Chief Financial Officer of Groupe Sovac Auto Financial Services based in
Paris, France. He earned a Bachelor of Arts in International
Relations/Economics, graduating Cum Laude with Honors in Economics, from
Colgate University in Hamilton, New York as well as completed INSEAD's global
"AngioDynamics is at the beginning of an exciting growth phase," said Mr.
Frost. "The Company's innovation and dedication to operational excellence is
impressive, as is the strong international growth. The team has successfully
integrated the Navilyst operations and has completed an extremely exciting
acquisition with high growth potential in Vortex. I look forward to working
with Joe DeVivo and the team to capitalize on these opportunities and build
shareholder value. Additionally, I appreciate Joe Gersuk's dedication to
ensuring a smooth transition."
AngioDynamics Inc. is a leading provider of innovative, minimally invasive
medical devices used by professional healthcare providers for vascular access,
surgery, peripheral vascular disease and oncology. AngioDynamics' diverse
product lines include market-leading ablation systems, fluid management
systems, vascular access products, angiographic products and accessories,
angioplasty products, drainage products, thrombolytic products and venous
products. More information is available at www.AngioDynamics.com.
AngioDynamics and the AngioDynamics logo are trademarks and/or registered
trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements regarding
AngioDynamics' expected future financial position, results of operations, cash
flows, business strategy, budgets, projected costs, capital expenditures,
products, competitive positions, growth opportunities, plans and objectives of
management for future operations, as well as statements that include the words
such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes,"
"seeks," "estimates," "optimistic," or variations of such words and similar
expressions, are forward-looking statements. These forward looking statements
are not guarantees of future performance and are subject to risks and
uncertainties. Investors are cautioned that actual events or results may
differ from AngioDynamics' expectations. Factors that may affect the actual
results achieved by AngioDynamics include, without limitation, the ability of
AngioDynamics to develop its existing and new products, technological advances
and patents attained by competitors, future actions by the FDA or other
regulatory agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials, overall economic
conditions, the results of on-going litigation, the effects of economic,
credit and capital market conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, the effects on
pricing from group purchasing organizations and competition, the ability of
AngioDynamics to integrate purchased businesses, including Navilyst Medical
and its products, R&D capabilities, infrastructure and employees as well as
the risk factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the year ended
May 31, 2012.AngioDynamics does not assume any obligation to publicly update
or revise any forward-looking statements for any reason.
CONTACT: Investor Relations Contacts:
EVC Group, Inc.
Jamar Ismail/Robert Jones
(415) 568-9348; (646) 201-5447
EVC Group, Inc.
Press spacebar to pause and continue. Press esc to stop.